Drug Profile
CER 209
Alternative Names: CER-209Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Cerenis Therapeutics
- Developer ABIONYX Pharma
- Class Antihyperlipidaemics; Hepatoprotectants; Vascular disorder therapies
- Mechanism of Action P2RY13 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Dyslipidaemias; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Atherosclerosis in Unknown
- 28 Sep 2022 No recent reports of development identified for phase-I development in Dyslipidaemias in Unknown (PO)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease in Unknown (PO)